OBIO Governance

 

OBIO operates within a good governance framework and is accountable to its members and stakeholders 

 

Board of Directors


Michael Cloutier, OBIO Board Chair
Canadian Partner, Mirador Global

An Executive Leader & Human Resources Strategist with demonstrated success at national and global levels within the Pharmaceutical, Biotech and Health Sciences industries. Identifies, initiates and creates strategic plans for organizational transformation and performance enhancement. Delivers results through building and maintaining strong relationships internally and externally across all stakeholder populations. Recognized as a focused and ethical leader who demonstrates linear and abstract thinking to meet and exceed the needs of an organization.


board-of-directors-images-finals-gail.jpg

Gail Garland, OBIO Director
Chief Executive Officer
Ontario Bioscience Innovation Organization (OBIO)

Gail founded OBIO in 2009 following twenty years of experience including senior roles the banking, pharma, biotech and medical devices industries.  The Ontario Bioscience Innovation Organization (OBIO) is a not-for-profit, membership-based organization engaged in the development of an integrated health innovation economy for Ontario and one that will become a global leader in providing health technology products and services to the international marketplace. OBIO advances this goal through advocacy, promotion and strategic leadership and via collaborative partnerships with industry, academia, patients and government. OBIO developed and implemented OBEST (Ontario Bioscience Economic Strategy Team) a province-wide strategic vision to support the growth and viability of Ontario’s bioscience industry.  

Under Gail’s leadership, OBIO leads several multi-stakeholder, cross-disciplinary collaborative initiatives to advance industry’s cause.  In 2013, OBIO launched CAAP®, the ‘Capital Access Advisory Program’ to increase deal flow for high potential early stage companies.  In 2015, OBIO launched Pre-CAAP to help boost investability of post seed stage companies, as well as, prepare companies for OBIO’s CAAP program.  The OBIO CAAP program receives funding from both the Ontario Provincial and Federal (Federal Economic Development Agency) governments.  

Gail serves on the Dean’s Advisory Council, Faculty of Science, Ryerson University; the Biotechnology Advisory Committee at Humber College and the Canadian Life Sciences Advisory Counsel for Springboard Enterprises.  Gail is the Industry Chair of the OBIO MPP Health Sciences Caucus and serves on the Council for Innovation Procurement in Healthcare (Conference Board of Canada).  She has advocated for the future of the health science industry on national television and has written extensively on the topic with numerous publications in the national press and international and industry publications. 

Gail holds a Chartered Director (CDir) designation in governance (McMaster); an MBA from the Rotman School of Management, University of Toronto and a BSc. (Carleton University)


Dr David Young, MD, OBIO Director
CEO KisoJi Biotechnology Inc

David Young, MD, is the Founder and CEO of Kisoji Biotechnology Inc. Previously he was the Founder, CSO and CEO of ARIUS, a biotechnology company which was publicly traded on the TSX until the successful sale of the company in 2008 to F. Hoffman-La Roche. ARIUS partnered with leading companies such as Genentech, Takeda Pharmaceuticals, and Protein Design Labs. Dr. Young did his surgical and science training at the University of Toronto, where he received over 15 scholarships or awards. He is the inventor or author on over 200 patents and scientific papers. He is a recognized entrepreneur and received the Entrepreneur of the Year award from the Association of Chinese Canadian Entrepreneurs. Dr. Young is the founding Chairman of the Ontario Biotechnology Innovation Organization; a director of MabNet, a NSERC Strategic Network and a director of the St. Michael’s Hospital Foundation.


Jeremy Bridge-Cook, OBIO Director
CEO, RNA Diagnostics

Dr. Bridge-Cook was named Senior Vice President of Research and Development in May 2012. Previously he served as Senior Vice President of the Assay Group and Vice President, Luminex Molecular Diagnostics. He also served at Tm Bioscience, which became Luminex Molecular Diagnostics following the acquisition of Tm Bioscience by Luminex in March 2007. Dr. Bridge-Cook joined Tm Bioscience in July 2000 as Director of Business Development and served in various capacities thereafter, including Vice President of Business Development, Vice President of Marketing & Business Development, and Senior Vice President of Corporate Development. Prior to joining Tm, Dr. Bridge-Cook worked as a venture capital investment analyst at MDS Capital Corporation and University Medical Discoveries Inc. Dr. Bridge-Cook has a Ph.D. in immunology from the University of Toronto.


Shelley Boyd, OBIO Director
CEO, Translatum Medicus

Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina. She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California. She is director of the Ocular Phenotyping Facility of the Toronto Centre for Phenogenomics, and the Walter Retinal Regeneration laboratory. She is Assistant Professor of Ophthalmology & Vision Sciences, with cross-appointment to Biomedical Engineering, McMaster University. Shelley was formerly Head of the Ocular Angiogenesis Research Program, worldwide, with Novartis (Switzerland), overseeing pre-clinical and translational aspects of the Ranibizumab program.


Adam Buckley, OBIO Director
Vice President, Operations, VBI Vaccines

Adam co-founded VBI Vaccines in 2002. He has been responsible for a number of roles through VBI’s development stages, including business development, corporate development, finance and operations. His efforts included attracting seed capital to VBI, developing its first business plan, protecting intellectual property and structuring the company. He had an active role in the company’s Series A financing, raising $35.7 million (U.S.), and has led several key technology acquisitions for the company, including the acquisition of Epixis S.A. in 2011 which provided VBI with one of its core platform technologies. Most recently, Adam has held operational responsibilities for the company’s research and development site in Ottawa, Canada, leading efforts for the efficient and milestone driven development of the company’s vaccine products and platforms. Mr. Buckley is a recent recipient of the Ottawa Business Journal’s “Top 40 Under 40” award and obtained his M.B.A. and B.Sc. at McMaster University in Hamilton, Ontario.


board-of-directors-images-finals-cynthia.jpg

M. Cynthia Goh, OBIO Director
Academic Director, Banting and Best Innovation Center

M. Cynthia Goh is Professor at the Department of Chemistry, the Institute of Medical Science, the Munk School of Global Affairs, and Academic Director, Banting and Best Innovation Center. She received her PhD from the University of California at Los Angeles, and carried out postdoctoral fellowships at Columbia University and the University of California, Berkeley, prior to taking a faculty position at the University of Toronto. She has a diverse set of research interests, including fundamental studies of complex systems biomaterials, interfaces, probe microscopy, the development of new research instrumentation and nanotechnology. She is also known for her interest the translation of scientific discovery to technology and products, and the education of scientist-entrepreneurs. Together with her students, she co-founded 6 companies including Axela Inc (www.axelabiosensors.com), Vive Crop Protection (www.vivecrop.com) and Sciventions (www.sciventions.com), as well as Entrepreneurship101 at MaRS, the flagship entrepreneur training program of the MaRS Discovery District, with thousands registered attendees annually. In 2010, she introduced Techno, a one-month intensive training program specifically geared for university scientists intending to build a tech-based company. Techno2010 to 2014 have led to the creation of over 60 start-ups based on the results of scientific research, many of which now have sales and follow-on funding.


board-of-directors-images-finals-graziadei.jpg

Jim Graziadei, OBIO Director
Senior Vice President, Siemens Healthineers Canada (former)

As the former Senior Vice President of Siemens Healthineers Canada, Mr. Graziadei was responsible for the overall strategic direction and management of the Healthcare Sector business, including the Imaging & Therapy, Clinical Products and Diagnostics divisions. Providing a full range of integrated services including multi-vendor solutions, asset planning and management, Siemens is a leading healthcare supplier and consultant in the field of image management and networking systems. Mr. Graziadei has over 20 years sales, marketing and general management experience. Most recently he was General Manager of Siemens Diagnostics in Canada, and was responsible for achieving strategic and financial goals by developing a high performance structure and culture. Mr. Graziadei holds a Bachelor of Science in Business Administration from California State University in Sacramento. Mr Graziadei is a member of MEDEC.


board-of-directors-images-finals-kelly.jpg

Kelly Holman, OBIO Director
Co-Founder and Managing Director, Genesys Capital

Mr. Holman is co-Founder and Managing Director of Genesys Capital. Since co-founding the firm in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $150 million across 28 investments. He currently serves on the Board of Directors of Functional Neuromodulation, Impopharma and InVitae (observer). From 2001-2013, Kelly served on the Board of Directors of Epocal (acquired by Alere in 2013). Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s University.


board-of-directors-images-finals-stephan.jpg

Stefan Larson, OBIO Director
Entrepreneur in Residence, Versant Ventures. CEO , Northern BIologics

Stefan Larson is an Entrepreneur-in-Residence at Versant Ventures, where he serves as President of Blueline Bioscience, a Toronto-based biotechnology incubator. He is also the founding CEO of Northern Biologics, an antibody discovery company located in the MaRS Centre. Stefan joined Versant after spending three years as the co-founder and CEO of Tornado Medical Systems, a revenue-stage medical imaging and spectroscopy company. He previously held the position of Associate Principal with McKinsey & Company, serving global clients in healthcare and technology. He is currently a director of the Ontario Bioscience Innovation Organization (OBIO), and of MaRS DD and is a recipient of the Arbor Award for Exceptional Volunteer Service to the University of Toronto. Stefan received his B.Sc. in Biology from McGill University, and his M.Sc. in Molecular and Medical Genetics from the University of Toronto. He completed his Ph.D. in Biophysics at Stanford University, where he helped build and launch Folding@home, the world’s most successful scientific publicly distributed computing platform.


board-of-directors-images-finals-richard.jpg

Richard Meadows, OBIO Director
Venture Capital Professional

Richard Meadows has been one of two managing partners at CTI Life Sciences Fund. He was formerly a successful investor at Vantage Point Venture Partners and CDP Capital Technology Ventures. Mr. Meadows was on the boards as an early investor in Enobia Pharma, which sold for $1.1 billion to Alexion Pharmaceuticals, and TargeGen which sold in June 2010 to Sanofi for $560 million. Mr. Meadows has extensive experience in operations, general management in biopharmaceuticals, and finance. He has made and managed investments in the cancer, cardiovascular, auto-inflammatory and immunology areas. Richard was recently recognized by Forbes as one of the top 10 life science investors in 2013.


board-of-directors-images-finals-terry.jpg

Terry McCool, OBIO Director
VP Corporate Affairs, Eli Lilly Canada (retired)

Mr. D. Terry McCool is the Vice President of Corporate Affairs at Eli Lilly Canada. In this role he is responsible for all aspects of corporate affairs including federal and provincial government affairs, policy development, provincial and private reimbursement , pricing, health economics, advocacy relations, communications, strategic partnerships and public affairs. Since joining Eli Lilly Canada, Mr. McCool has held various senior management positions including Director of Sales and Director of Human Resources. He is also a member of the Senior Management Team and the Board of Directors of Eli Lilly Canada. Mr. McCool sits on a number of industry association committees at the Pharmaceutical Research and Manufacturers of America (PhRMA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D). He is Chair of the Intellectual Property Committee at Rx&D, and Chair of the Canada Committee at PhRMA, a Director and Member of the Executive Committee at the Institute of Health Economics in Alberta, a member of the Dean’s Advisory Committee for the University of Alberta’s Faculty of Pharmacy and a member of the Life Sciences Advisory Board for the Department of Foreign Affairs and International Trade. He also chairs the Ottawa Liaison Committee for the Chamber of Commerce in Ottawa. Mr. McCool has a Bachelor of Science in Pharmacy from the University of Alberta and attended the Advanced Management program at Kelley School of Business at Indiana University.


board-of-directors-images-finals-steve.jpg

Steven Plymale, OBIO Director
COO, Profound Medical Inc. (former)

Steven Plymale is the former CEO of Profound Medical Inc. Prior to the chief executive role at Profound, Mr. Plymale was VP and General Manager of Xltek, a $60M neurology division of Natus Medical Incorporated based in Oakville, Ontario. Mr. Plymale’s 25-year career in medical devices includes working with start-ups, early stage companies, and turnaround operations. He has held executive roles in several high tech medical device companies such as CryoCath Technologies, Claron Technologies and the Bluehaven Consulting Group. Since 2008 he has expanded his skills and experience to include working in corporate governance and Board appointments. He has been an active member of the Institute of Corporate Directors since 2007 and recently accepted enrollment to the prestigious Directors Education Program co-sponsored by the Rotman School of Management, University of Toronto. Mr. Plymale has a B.Sc. Health Administration from St. Joseph’s University and a B.Sc. Radiological Sciences from the Veterans Administration School of Radiological Sciences, both in New York. He is a recipient of the latter institution’s Mallinkrodt Award for Academic Excellence. He is also a sitting member of the Life Sciences Advisory Board for the Canadian Department of Foreign Affairs and International Trade and a faculty member with the Medical Devices Innovation Institute.


board-of-directors-images-finals-ian.jpg

Dr. Ian Smith, OBIO Director
President, Innovative Biodiagnostics Inc

Dr. Ian Smith began his National Research Council (NRC) career in Ottawa as a Research Officer specializing in magnetic resonance. In 1987, he became Director General of the NRC Institute for Biological Sciences, Ottawa. In 1992, he founded the Institute for Biodiagnostics in Winnipeg as its first Director General. The Institute focuses on the development and commercialization of medical devices for the non-invasive diagnosis of disease.

Dr. Smith is dedicated to early detection and treatment of disease and using this knowledge to advance the state of medicine and the economy. He is a passionate mover for the commercialization of the products of research, and has started nine companies with a present value of close to $1 billion. In 2013, he retired from NRC to help build a spin-off company, Innovative Biodiagnostics, specializing in tests for colon cancer and breast cancer.

He was appointed Officer of the Order of Canada in 2008 for his leadership in the advancement, development and commercialization of Canada’s diagnostic technologies, notably magnetic resonance imaging, in the field of health care. In addition, Dr. Smith received the 2008 Outstanding Achievement Award of the Public Service of Canada, presented to individuals who have displayed long-term excellence throughout their careers in Canada’s public service. He was awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for his contributions.

He holds a number of honorary degrees, including Phil.Dr. from Stockholm University. He is past president of the International Union for Pure and Applied Biophysics and a member of advisory boards of various companies and agencies. Dr. Smith currently is the Chair of the Board of Directors for the Centre for Imaging Technology Commercialization and President, Innovative Biodiagnostics Inc.


board-of-directors-images-finals-mark.jpg

Mark Steedman, OBIO Director
Vice President, Business Development, Interface Biologics

Mark coordinated the formation of Interface Biologics in December 2001 and is currently responsible for managing the corporate business aspects of the corporation. In 2004 Mark raised $12M in a Series A round and grew the team from 0 to 15 people and helped recruit the senior management team. Mark was instrumental in landing early deals with several large medical device manufacturers, and oversaw company operations from early R&D to its first revenues in 2004. These early deals ultimately led to FDA approval for multiple medical device products. Mark holds degrees in Applied Science in Engineering, a Bachelor of Arts in Biology both from Queen’s University and an MBA from Wilfrid Laurier University.


Cathy Szabo, OBIO Director
CEO, Providence Care

Cathy Szabo is the President & Chief Executive Officer of Providence Care, the leading provider of Aging, Mental Health and Rehabilitative care in southeastern Ontario. In her over 30 years of experience, Cathy has focused on Health System Improvement, creating organizational cultures of quality and excellence while delivering patient care that meets individuals needs. Under her leadership, Central CCAC developed a Medication Management Support Services program which was awarded Best Innovation Healthcare Practice in Canada by the National Research Corporation (NRC).  Additionally, this program was recognized at the bronze level by the Institute for Public Administration of Canada (IPAC).

A dedicated advocate for healthcare, Cathy is an active member of the Knowledge Exchange Board, Canadian Patient Safety Institute; the International Society for Quality in Health Care; Centre for Health System Design and Management, Conference Board of Canada; Osgoode Hall Health Law Program; and GS1 Canada Health Care Advisory Council.  In addition, Cathy is the Chair of Healthcare Insurance Reciprocal of Canada (HIROC). Throughout her career, Cathy has successfully delivered cost-effective models of care by applying evidence-based leading practices from around the globe to service delivery in Ontario.  Cathy holds a Master of Public Health, a Bachelor of Science in Nursing degree and a diploma of Clinical Administration from the Ontario Hospital Association.  She is a Registered Nurse and a Certified Health Executive with the Canadian College of Health Leaders.


board-of-directors-images-finals-chiu.jpg
 

Jung-Kay Chiu, OBIO Secretary
Partner, Norton Rose LLP

Jung-Kay Chiu practises in all areas of intellectual property law, with a focus on intellectual property acquisition, protection and exploitation in the field of biotechnology and medical devices. Mr. Chiu’s practice includes drafting and prosecuting patent applications, industrial designs and trade-marks, as well as patent licensing and other commercial transactions relating to intellectual property. Mr. Chiu is also routinely involved in preparing patent-related due diligence reports and patentability, infringement and validity opinions.

Mr. Chiu joined the Norton Rose Toronto office in 2003 after practising corporate commercial law and intellectual property law with another major law firm in Canada. His technical experience includes conducting post-graduate research in molecular biology at the University of Toronto, and his technical background includes genetics, molecular biology, biotechnology and biochemistry. Mr. Chiu is Canadian Team Leader of the Patents and IP Transaction team.

 

board-of-directors-images-finals-bob.jpg
 

Prabh (Bob) Singh, OBIO Treasurer
Partner, PWC

Prabh (Bob) Singh is an associate partner in the Tax Services practice of Price Waterhouse Coopers LLP working in the Mississauga office. As an associate partner in Corporate Tax Services, Bob delivers high quality value-added tax solutions by focusing on the goals and objectives of his clients. He has extensive experience in various aspects of Canadian federal and provincial income and capital taxes, including domestic tax planning and corporate reorganizations. Bob provides tax planning and compliance services for both medium-sized businesses and subsidiaries of large multinational corporations primarily in the pharmaceuticals and life sciences. He is very familiar
with PwC’s service offerings and always looks for opportunities to link relevant PwC specialists to meet the needs of his clients.

He has been heavily involved in helping his pharmaceutical and life sciences clients maximize their tax incentive claims under both the federal and provincial Scientific Research and Experimental Development (SR&ED) programs. In this role, he assists clients with the review of the financial aspects of their SR&ED claims. He also coordinates with PwC’s SR&ED engineers to address the scientific aspects of the SR&ED claim. Bob is a member of the Institute of Chartered Accountants of Ontario and a University of Toronto alumnus.